--- title: "TUS-PHARMA: The subsidiary Hengdao Pathology, in which it holds shares, assists Ruijin Hospital in collaborating with Huawei to launch the \"Ruizhi Pathology Large Model.\"" type: "News" locale: "en" url: "https://longbridge.com/en/news/228960663.md" description: "TUS-PHARMA's invested company, Hengdao Medical, collaborated with Huawei to launch the \"RuiPath\" large model at Ruijin Hospital. The model was released at the \"2025 Medical Artificial Intelligence and Precision Diagnosis Development Forum.\" Since 2021, Hengdao Medical has assisted Ruijin Hospital in building a digital pathology system, establishing the country's first full-process digital smart pathology system, providing data foundation and technical support. The WisPath® system will work together with the \"RuiPath\" large model to promote the realization of domestic pathology large models" datetime: "2025-02-20T04:41:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/228960663.md) - [en](https://longbridge.com/en/news/228960663.md) - [zh-HK](https://longbridge.com/zh-HK/news/228960663.md) generator: "portal-rs" --- # TUS-PHARMA: The subsidiary Hengdao Pathology, in which it holds shares, assists Ruijin Hospital in collaborating with Huawei to launch the "Ruizhi Pathology Large Model." On February 20th, according to the official WeChat account of TUS-PHARMA, the "2025 Medical Artificial Intelligence and Precision Diagnosis Development Forum" was held at Ruijin Hospital in Shanghai on the afternoon of February 18th. This grand event gathered numerous industry experts, scholars, and corporate representatives to witness the launch of the "RuiPath" large model for pathology. Hengdao Medical has been assisting the pathology department of Ruijin Hospital in the construction of a digital pathology department since 2021, and has taken the lead in the country to establish an "end-to-end full-process digital intelligent pathology system," accumulating a library of millions of digital pathology slides. Hengdao Medical's WisPath® full-process intelligent digital pathology system provides a solid data foundation and technical support for the construction of the "RuiPath" large model for pathology. The WisPath® system will work together with the "RuiPath" large model for pathology in the future to help realize the "new domestic pathology large model" intelligent platform, truly becoming the "divine assistant" for pathologists ### Related Stocks - [000590.CN](https://longbridge.com/en/quote/000590.CN.md) - [HUAWEI.NA](https://longbridge.com/en/quote/HUAWEI.NA.md) ## Related News & Research - [Cho Kwang Sik, Related Parties Raise PNC Technologies Stake to 47.18% From 38.07%](https://longbridge.com/en/news/305620649.md) - [EvoNext releases Ascend Sport Technology audited accounts ahead of merger](https://longbridge.com/en/news/305620792.md) - [CLSA: Z.AI 's Coding Capability Combined With Self-Improvement Supports AI Growth](https://longbridge.com/en/news/305619610.md) - [BELRISE: Manufacturing-led growth and expanding assembly, electronics and aerospace wins underpin unchanged guidance](https://longbridge.com/en/news/305620691.md) - [TA Securities deems Epicon's RM 543.16 million acquisitions fair](https://longbridge.com/en/news/305620644.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**